|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
| We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry. |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/02/24 Zeo ScientifiX, Inc. 8-K:5 4/01/24 10:183K Empire Filings/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 27K 5: R1 Cover HTML 42K 7: XML IDEA XML File -- Filing Summary XML 11K 10: XML XBRL Instance -- zeoscientifixinc_8k_htm XML 15K 6: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 3: EX-101.LAB XBRL Labels -- ocel-20240401_lab XML 96K 4: EX-101.PRE XBRL Presentations -- ocel-20240401_pre XML 63K 2: EX-101.SCH XBRL Schema -- ocel-20240401 XSD 12K 8: JSON XBRL Instance as JSON Data -- MetaLinks 25± 33K 9: ZIP XBRL Zipped Folder -- 0001829126-24-002156-xbrl Zip 15K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): i April 1, 2024
(Exact name of registrant as specified in its charter)
| i Nevada | i 000-55008 | i 47-4180540 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| i 33314 | ||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: i (888) i 963-7881
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
| None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(a) On April 1, 2024, our board of directors awarded stock grants of 125,000 and 62,500 shares of our common stock to Jerry Glauser and Leathem Stearn or their nominees, respectively. Messrs. Glauser and Stearn are members of our board of directors. The grants, which were made under our 2021 Incentive Stock Plan (the “2021 Plan”), vested in full as of the date of grant.
(b) On April 1, 2024, our board of directors granted stock options to purchase 5,000 shares of our common stock under the 2021 Plan to each of Chuck Bretz, Jerry Glauser, Leathem Stearn and Gurvinder Pal Singh, our independent directors. The options vest as to 2,500 shares as of the grant date and as to the remaining balance of 2,500 shares on September 23, 2024, and are exercisable for a period of five (5) years from the date of grant at an exercise price of $2.00 per share.
(c) The compensation committee of our board of directors authorized an increase in the base salary of Ian T. Bothwell, ZEO’s Chief Financial Officer, to $250,000, retroactive to January 1, 2024.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: April 2, 2024 | ZEO SCIENTIFIX, INC. | |
| By: | /s/ Harry Leider | |
| Harry Leider, M.D., Chief Executive Officer | ||
2
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 9/23/24 | None on these Dates | |||
| Filed on: | 4/2/24 | |||
| For Period end: | 4/1/24 | |||
| 1/1/24 | ||||
| List all Filings | ||||